Endo International (ENDP) – Major News
-
Endo International (ENDP) Tops Q1 EPS by 20c, Guidance Misses Consensus
-
Endo International (ENDP) Tops Q4 EPS by 17c
-
Endo International (ENDP) Tops Q3 EPS by 34c, Offers Guidance
-
Endo International (ENDP) Tops Q2 EPS by 17c, Offers FY Guidance
-
Endo International (ENDP) Tops Q1 EPS by 25c
-
Endo International (ENDP) Tops Q4 EPS by 27c
-
Endo International (ENDP) Tops Q3 EPS by 38c, Updates Guidance
-
Endo International (ENDP) to Acquire BioSpecifics Technologies (BSTC) for $88.50/Share in Cash
-
Endo International (ENDP) Tops Q2 EPS by 31c, Guidance Misses
-
Endo International (ENDP) Tops Q1 EPS by 41c
-
Endo International (ENDP) Tops Q4 EPS by 17c, Revenues Beat; Provides FY20 EPS/Revenue Outlook
-
Endo International (ENDP) Tops Q3 EPS by 7c, Offers FY Guidance
-
Endo International (ENDP) Tops Q1 EPS by 10c, Revenues Beat; Offers FY19 EPS/Revenue Guidance
-
Endo International (ENDP) Tops Q4 EPS by 16c, FY EPS Guidance Misses
-
Endo International (ENDP) Tops Q3 EPS by 12c, Guidance Tops Views
-
Endo International (ENDP) Tops Q2 EPS by 22c, Lifts FY Guidance
-
Endo International (ENDP) Tops Q1 EPS by 12c, Affirms Gudiance
-
Endo International (ENDP) Tops Q4 EPS by 16c; Guides FY18 Below Views
-
Endo Int'l (ENDP) Tops Q3 EPS by 24c; Reaffirms
-
Endo Int'l (ENDP) Tops Q2 EPS by 20c, Offers FY Guidance
-
Endo Int'l (ENDP) to Resolve Nearly All U.S. Mesh Product Liability Claim
-
Endo Int'l (ENDP) Confirms Removal of OPANA ER from Market, Sees Pre-Tax Charge of $20M
-
FDA requests removal of Endo's (ENDP) Opana ER for risks related to abuse
-
Endo Int'l (ENDP) Tops Q1 EPS by 13c; Reaffirms
-
Endo Int'l (ENDP) Confirms FDA Advisory Committee Voted OPANA ER Risks Outweigh Benefits
-
Endo (ENDP) FDA Panel Says Opana ER Benefits No Longer Outweigh Risk; Votes 18-8 Opana ER Doesn't Outweigh Risk - Bloomberg
-
Endo Int'l (ENDP) Tops Q4 EPS by 14c
-
Endo Int'l (ENDP) Tops Q3 EPS by 20c
-
Endo Int'l (ENDP) CEO De Silva Resigns; New CEO Appointed; Guidance Reaffirmed
-
Endo Int'l (ENDP) Tops Q2 EPS by 12c, Affirms Guidance
-
Endo Int'l (ENDP) Unit Receives New U.S. Patent Related to Vasostrict
-
Endo Int'l (ENDP) Tops Q1 EPS by 4c, Guides FY Well Below Consensus
-
Endo Int'l (ENDP) Tops Q4 EPS by 9c; Guides FY16 EPS
-
Endo (ENDP) Tops Q3 EPS by 3c, Affirms FY Guidance
-
Endo Int'l (ENDP) Tops Q2 EPS by 6c
-
Endo Int'l (ENDP) to Acquire Par Pharma in ~$8.05B Deal
-
Endo Int'l (ENDP) Tops Q1 EPS by 11c; Boosts FY15 EPS Outlook
-
Endo Int'l (ENDP) Announces Withdraw of Salix Pharma (SLXP) Bid
-
Salix Pharma (SLXP) Surges on Reports of Competing Bid from Endo (ENDP)
-
Endo Int'l (ENDP) Tops Q4 EPS by 4c; Guides FY15 EPS, Revs Below Expectations
-
Boston Scientific (BSX) to Acquire Endo's AMS Urology Portfolio in $1.65B Deal
-
Endo Int'l (ENDP) Tops Q3 EPS by 16c
-
Endo Int'l (ENDP) to Acquire Auxilium (AUXL) in $2.6B Deal
-
Endo (ENDP) Makes $28.10/Share Bid for Auxilium Pharma (AUXL)
-
Endo International plc (ENDP) Tops Q2 EPS Views; Boosts Profit Outlook
-
Endo International plc (ENDP) Tops Q1 EPS by 8c
-
Endo Pharmaceuticals Holdings (ENDP) Tops Q4 EPS by 3c; Guides FY14 EPS Below Views
-
Endo Pharma (ENDP) Tops Q3 EPS by 23c; Boosts FY13 Outlook
-
Endo Health (ENDP) to Acquire Paladin Labs in $1.6B Deal
-
Endo Pharmaceuticals Holdings (ENDP) Tops Q2 EPS by 27c
Back to ENDP Stock Lookup